![Abraham Verghese](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Abraham Verghese have a current job as a Director at Athos Therapeutics, Inc.
Abraham Verghese active positions
Companies | Position | Start |
---|---|---|
Athos Therapeutics, Inc.
![]() Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | Director/Board Member | 2022-05-17 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Athos Therapeutics, Inc.
![]() Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | Health Technology |
- Stock Market
- Insiders
- Abraham Verghese